Rabies vaccine for human beings

A rabies vaccine and vaccine technology, which is applied in the direction of medical preparations containing active ingredients, antibody medical ingredients, peptides, etc., can solve the problems of increasing vaccine side effects, etc., and achieve the goal of overcoming immune limitations, good immune effect and safety Effect

Inactive Publication Date: 2012-07-04
SHANGHAI ZERUN BIOTECHNOLOGY CO LTD
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It contains components that have nothing to do with antigens, such as viral miscellaneous proteins, viral nucleic acids and lipids, and residual proteins of tissue proteins from cultured viruses. When the antigen content of the virus is increased, these miscellaneous proteins also increase, so the side effects of the vaccine are enlarged

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1 lysing and extraction and purification of whole rabies virus particles

[0030] The Vero cells were cultured at 37°C and passed through four consecutive passages. After the 4th passage cells are cultured for 3-5 days, they are rinsed with phosphate buffer, and the inoculation virus titer is not less than 7.5LgLD 50 / ml of rabies virus fixed virus CTN-1V strain. Then add cell maintenance solution and incubate at 35°C for 24 hours. Replace with fresh cell maintenance solution, and continue to culture for 2-4 days according to the above conditions. When the cytopathic CPE reaches ++~+++, harvest and combine the virus solution. Add β-propiolactone at a ratio of 1:4000 and place at 22°C for 8 days to inactivate the virus. After passing the inactivation test, it was concentrated by ultrafiltration with a 100KD filter membrane. 10 mg / ml protamine sulfate was added to the concentrated virus liquid to make the final concentration 0.1 mg / ml, centrifuged at 8000 r...

Embodiment 2

[0032] Get the human rabies virus particle cleavage protein (mainly containing the outer membrane fragment of the cleavage virus particle) and tetanus toxoid stock solution (Wuhan Institute of Biological Products) prepared above, and the mixing ratio according to the antigen content is: viral protein 10-150 μ g / dose ; The dosage of tetanus toxoid is 3Lf / dose-10Lf / dose; respectively combined to make liquid vaccine, then packaged, and finally tested and packaged.

Embodiment 3

[0034] Get human rabies purified stock solution (diploid cells) (National Institute for the Control of Pharmaceutical and Biological Products), rabies virus particle lysate protein and tetanus toxoid stock solution (Wuhan Institute of Biological Products) to make liquid vaccine according to the proportions in Table 1 . Human rabies vaccine was set as the control group, in which only 1% human serum albumin was added as the protective agent, and the specificity experiments of the four combined vaccines were carried out according to the method of the third part of the Chinese Pharmacopoeia. The experimental results are all qualified, indicating that the vaccine added with tetanus toxoid lysate protein of rabies virus particles is safe and effective.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a rabies vaccine for human beings, which contains an outer membrane fragment of a split rabies virus particle and tetanus toxoid; the outer membrane fragment comprises furcella and matrix protein, wherein each dosage of rabies vaccine for human beings contains 10-150 micrograms of virus protein; and the dosage of the tetanus toxoid is 3-10 Lf/dosage. Compared with the existing virus purification stock solution, the rabies vaccine for human beings contains less other proteins, has higher immunogenicity and effect, and is more secure for use.

Description

technical field [0001] The invention relates to the field of medical prevention, in particular to a human rabies vaccine. Background technique [0002] Rabies is an acute infectious disease caused by rabies virus infection, and is a zoonotic acute infectious disease. Rabies kills more than 50,000 people each year, 99 percent of which occur in Asia, Africa and South America. [0003] Rabies virus (RV) is a highly neurotropic virus. It is a non-segmented negative-strand RNA virus in the rhabdoviridae family Rhabdovirus. Stranded RNA, the pathogen that causes rabies. Rabies virus has two main antigens: one is the glycoprotein antigen on the outer membrane of the virus, which can bind to the acetylcholine receptor to make the virus neurotoxic, and to produce neutralizing antibodies and hemagglutination inhibitory antibodies in the body. role; the other is the inner nuclear protein antigen, which can make the body produce complement-fixing antibodies and precipitins, without p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/205A61K39/39C07K14/145A61P31/14
Inventor 沈琼张高峡
Owner SHANGHAI ZERUN BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap